Loading... Please wait...

Our Newsletter


Ciproxin (Ciprofloxacin) 500mg by Bayer x 10 Strips

  • Image 1
Price:
$78.00
Weight:
100.00 Grams
Shipping:
Calculated at checkout
Bookmark and Share


Product Description

Indications: Ciprofloxacin is indicated for the treatment of the following infections caused by sensitive bacteria: Adults: Severe systemic infections: e.g. septicaemia, bacteraemia, peritonitis, infections in immunosuppressed patients with haematological or solid tumours and in patients in intensive care units with specific problems such as infected burns. Respiratory tract infections: e.g. lobar and bronchopneumonia, acute and chronic bronchitis, acute exacerbation of cystic fibrosis, bronchiectasis, empyema. Ciprofloxacin is not recommended as first-line therapy for the treatment of pneumococcal pneumonia. Ciprofloxacin may be used for treating Gram-negative pneumonia. Ear, nose and throat infections: e.g. mastoiditis, otitis media and sinusitis, especially if due to Gram-negative bacteria (including Pseudomonas spp.). Ciprofloxacin is not recommended for the treatment of acute tonsillitis. Eye infections: e.g. bacterial conjunctivitis. Urinary tract infections: e.g. uncomplicated and complicated urethritis, cystitis, pyelonephritis, prostatitis, epididymitis. Skin and soft tissue infections: e.g. infected ulcers, wound infections, abscesses, cellulitis, otitis externa, erysipelas, infected burns. Bone and joint infections: e.g. osteomyelitis, septic arthritis Intra-abdominal infections: e.g. peritonitis, intra-abdominal abscesses. Infections of the biliary tract: e.g. cholangitis, cholecystitis, empyema of the gall bladder. Gastro-intestinal infections: e.g.enteric fever, infective diarrhoea. Pelvic infections: e.g. salpingitis, endometritis, pelvic inflammatory disease. Gonorrhoea: including urethral, rectal and pharyngeal gonorrhoea caused by ß-lactamase producing organisms or organisms moderately sensitive to penicillin. Children: For the treatment of acute pulmonary exacerbation of cystic fibrosis associated with P. aeruginosa infection in paediatric patients aged 5 – 17 years. Inhalation Anthrax in Adults and Children: To reduce the incidence or progression of disease following confirmed or suspected exposure to aerosolised Bacillus anthracis
Contra Indications: Ciprofloxacin is contra-indicated in patients who have shown hypersensitivity to ciprofloxacin or any of the excipients, or other quinolone anti-infectives. Except in cases of exacerbation of cystic fibrosis associated with P. aeruginosa (in patients aged 5- 17 years) and inhalation anthrax, ciprofloxacin is contra-indicated in children and growing adolescents unless the benefits of treatment are considered to outweigh the risks. Concurrent administration of ciprofloxacin and tizanidine is contraindicated since an undesirable increase in serum tizanidine concentrations associated with clinically relevant tizanidine-induced side-effects (hypotension, somnolence) can occur

 

Drug description Ciproxin Infusion

Drug description: Sterile solution for intravenous infusion
Generic name: Ciprofloxacin
Drug class description: 4-quinolones (quinolones)

 

 

Special precautions Ciproxin Infusion

In the event of hypersensitivity, which in some instances can occur after the first administration, therapy should be discontinued. Ciprofloxacin should be used with caution in epileptics and patients with a history of CNS disorders and only if the benefits of treatment are considered to outweigh the risk of possible CNS side-effects. CNS side-effects have been reported after first administration of ciprofloxacin in some patients. Treatment should be discontinued if the side-effects, depression or psychoses lead to self-endangering behaviour (See Adverse Reactions). Crystalluria related to the use of ciprofloxacin has been reported. Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided. Patients with a family history of or actual defects in glucose-6-phosphate dehydrogenase activity are prone to haemolytic reactions with quinolones, and so ciprofloxacin should be used with caution in these patients. Tendon inflammation and rupture may occur with quinolone antibiotics. Such reactions have been observed particularly in older patients and in those treated concurrently with corticosteroids. At the first sign of pain or inflammation, patients should discontinue ciprofloxacin and rest the affected limbs. There is a risk of pseudomembranous colitis with broad-spectrum antibiotics possibly leading to a fatal outcome. It is important to consider this in patients suffering from severe, persistent diarrhoea. With ciprofloxacin this effect has been reported rarely. If pseudomembranous colitis is suspected treatment with ciprofloxacin should be stopped and appropriate treatment given (e.g. oral vancomycin). Drugs that inhibit peristalsis must not be given. Ciprofloxacin has been shown to produce photosensitivity reactions. Patients taking ciprofloxacin should avoid direct exposure to excessive sunlight or UV-light. Therapy should be discontinued if photosensitisation (i.e., sunburn-like skin reactions) occurs. Laboratory tests may give abnormal findings if performed whilst patients are receiving ciprofloxacin, e.g. increased alkaline phosphatase; increases in liver function tests, e.g. transaminases and cholestatic jaundice, especially in patients with previous liver damage. In patients for whom sodium intake is of medical concern (e.g. patients with congestive heart failure, renal failure, nephrotic syndrome), the sodium content of Ciproxin Infusion should be taken into account